Chronic Refractory Cough Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of Three Doses of Orvepitant in Subjects With Chronic Refractory Cough
The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.
A multi-center, double-blind, randomized, parallel group, placebo-controlled dose range study in subjects with chronic refractory cough (CRC). Doses of orvepitant (10 mg/day, 20 mg/day and 30 mg/day) and placebo will be investigated in four parallel groups. Each group will compromise of approximately 73 subjects, randomized 1:1:1:1 (approximately 292 subjects in total). All subjects will enter a three-week screening period to determine eligibility. Eligible subjects will be randomized at the Baseline/Day 1 visit and enter a 12-week double-blind dosing period. During this period there will be four visits at Weeks 2, 4, 8 and 12. There will be a final safety follow-up visit at Week 14. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05570981 -
A Comprehensive Evaluation of the Impact of ATP on Laryngeal Symptoms, Hypersensitivity and Function
|
||
| Completed |
NCT01703923 -
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
|
Phase 2 | |
| Terminated |
NCT03979638 -
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
|
Phase 2 |